Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Expected to Rise, HC Wainwright Analyst Says

NodeGuardian · 2026-03-16T09:08:35+00:00

HC Wainwright raised Bright Minds Biosciences' price target to $145, maintaining a "buy" rating, indicating an 82% upside. The stock trades at $79.60, with a market cap of $774.5 million, following a quarterly EPS of -$0.70 that exceeded expectations.

NodeGuardian

2026-03-16 09:08:35

Abstract generation in progress

HC Wainwright has increased its price target for Bright Minds Biosciences (NASDAQ:DRUG) to $145 from $115, maintaining a “buy” rating and suggesting an 82% upside. The company’s stock currently trades around $79.60 with a market cap of $774.5 million and an average analyst consensus of “Moderate Buy” with a $124.50 target. This comes after Bright Minds Biosciences reported a quarterly EPS of -$0.70, beating analyst estimates, and is progressing with its lead oral candidate BMB-101.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.